ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

This study is currently recruiting participants.
Verified June 2012 by EKOS Corporation
Sponsor:
Information provided by (Responsible Party):
EKOS Corporation
ClinicalTrials.gov Identifier:
NCT01166997
First received: July 15, 2010
Last updated: June 27, 2012
Last verified: June 2012
  Purpose

The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.


Condition Intervention Phase
Submassive Pulmonary Embolism
Device: EkoSonic Endovascular System
Drug: Unfractionated heparin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism

Resource links provided by NLM:


Further study details as provided by EKOS Corporation:

Primary Outcome Measures:
  • Reduction of RV/LV ratio [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    RV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.


Estimated Enrollment: 50
Study Start Date: July 2010
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ultrasound accelerated thrombolysis
Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
Device: EkoSonic Endovascular System
The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
Active Comparator: Intravenous unfractionated heparin
Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
Drug: Unfractionated heparin
Intravenous unfractionated heparin used for anticoagulation treatment

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with acute PE symptoms < 14 days.
  • Filling defect by contrast-enhanced chest CT in at least one main or proximal lower lobe pulmonary artery
  • Right ventricular dysfunction confirmed by echocardiography where the RV/LV end diastolic diameter ratio is ≥ 1.0.

Exclusion Criteria:

  • Age less than 18 years or greater than 80 years
  • Index PE symptom duration > 14 days
  • Insufficient echocardiographic image quality in the apical or subcostal four-chamber view that prohibits the measurement of the right and left ventricular end-diastolic dimensions
  • Known significant bleeding risk
  • Administration of thrombolytic agents, e.g., tissue plasminogen activator, streptokinase, or urokinase, within the previous 4 days
  • Active bleeding
  • Known bleeding diathesis
  • Known coagulation disorder, platelet count < 100 000/mm3, or previous use of vitamin K antagonists with INR > 2.5
  • History of any intracranial or intraspinal surgery or trauma or intracranial/intraspinal bleed
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Recent (< 3 months) GI bleeding.
  • Recent (< 3 months) internal eye surgery or hemorrhagic retinopathy; recent (< 10 days) major surgery, cataract surgery, trauma, CPR, obstetrical delivery, or other invasive procedure.
  • Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
  • Estimated glomerular filtration rate (eGFR) < 50 ml/min as calculated by the Cockroft formula.
  • Hemodynamic collapse at presentation defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min, or drop of systolic blood pressure by at least 40 mm Hg for at least 15 min with signs of end organ hypoperfusion (cold extremities or low urinary output < 30 mL/h or mental confusion); or need for catecholamine administration to maintain adequate organ perfusion and a systolic blood pressure of > 90 mm Hg.
  • Severe hypertension on repeated readings (systolic > 180 mmHg or diastolic > 105 mmHg).
  • Pregnant, lactation or parturition within the previous 30 days (positive pregnancy test, women of childbearing age must be tested).
  • Participating in any other investigational drug or device study.
  • Life expectancy < 90 days.
  • Inability to comply with study assessments (e.g. due to geographic distance).
  • Previous enrollment in this study
  • Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.
  • Known right-to-left shunt, for example from large patent foramen ovale or atrial septal defect
  • Large (>10 mm) right atrial or right ventricular thrombus
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01166997

Contacts
Contact: Nils Kucher, Prof Dr med 42 79 82 55461 nils.kucher@insel.ch

Locations
Germany
Klinikum Lippe-Detmold Recruiting
Detmold, Germany, 32756
Contact: Ulrich Tebbe, Prof Dr Med     +49 (0) 5231 72-1181     ulrich.tebbe@uniklinikum-lippe.de    
Contact: Dirk Härtel, Dr         dirk.haertel@uniklinikum-lippe.de    
Principal Investigator: Ulrich Tebbe, Prof Dr med            
Klinikum Dortmund gGmbH Recruiting
Dortmund, Germany, 44137
Contact: Thomas Heitzer, Prof Dr med     +49 (0) 231 95321760     thomas.heizter@klinikumdo.de    
Principal Investigator: Thomas Heitzer, Prof Dr med            
Universitätsklinikum Carl Gustav Carus an der TU Dresden Recruiting
Dresden, Germany, 01307
Contact: Jan Beyer-Westendorf, Dr med     +49 (351) 458-3659     beyer.jan@uniklinikum-dresden.de    
Principal Investigator: Jan Beyer-Westendorf, Dr med            
Universitätsklinikum der Ernst-Moritz-Arndt-Universität, Recruiting
Greifswald, Germany, 17475
Contact: Klaus Empen, Dr. med     +49 (3834) 86 80505     empen@uni-greifswald.de    
Principal Investigator: Klaus Empen, Dr med            
Universitätsklinikum Heidelberg Recruiting
Heidelberg, Germany, 69120
Contact: Erwin Blessing, Prof Dr med     +49 (6221) 56-8676     Erwin.Blessing@med.uni-heidelberg.de    
Contact: Arthur Filusch, Dr         arthur.filusch@med.uni-heidelberg.de    
Principal Investigator: Erwin Blessing, Prof Dr med            
Klinikum der Ludwig-Maximilians-Universität (LMU) Recruiting
München, Germany, 81377
Contact: Christian Kupatt, Prof.Dr.med     +49 (0) 89 7095-3075     christian.kupatt@med.uni-muenchen.de    
Principal Investigator: Christian Kupatt, Prof Dr med            
Christliches Krankenhaus Quakenbrueck Not yet recruiting
Quakenbrueck, Germany, 49610
Contact: Bettina Goetting, Dr. med.     +49 (5431) 15-2888     b.goetting@ckq-gmbh.de    
Principal Investigator: Bettina Goetting, Dr. med.            
Helios Klinikum Siegburg Recruiting
Siegburg, Germany, 53721
Contact: Peter Boekstegers, Prof Dr med     +49 (2241) 18-2268     Peter.boekstegers@helios-kliniken.de    
Contact: Jan Horstkotte, Dr         jan.horstkotte@helios-kliniken.de    
Principal Investigator: Peter Boekstegers, Prof Dr med            
SRH Zentralklinikum Suhl Recruiting
Suhl, Germany, 98527
Contact: Torsten Fuss, Dr. med.     +49 (0) 3681 355438     torsten.fuss@zs.srh.de    
Principal Investigator: Torsten Fuss, Dr. med.            
Marienhospital Wesel, Klinik für Innere Medizin I Withdrawn
Wesel, Germany, 46483
Switzerland
Inselspital Bern, Kliniken fur Kardiologie and Angiologie Recruiting
Bern, Switzerland, 3010
Contact: Nils Kucher, MD     00 41 31 3220211     nils.kucher@insel.ch    
Contact: Mira Bartz-Batliner, Coordinator         mira.bartz-batliner@insel.ch    
Principal Investigator: Nils Kucher, Prof Dr med            
Sponsors and Collaborators
EKOS Corporation
Investigators
Principal Investigator: Nils Kucher, Prof Dr med Inselspital Bern, Kliniken für Angiologie und Kardiologie
  More Information

No publications provided

Responsible Party: EKOS Corporation
ClinicalTrials.gov Identifier: NCT01166997     History of Changes
Other Study ID Numbers: EKOS Protocol Number 08
Study First Received: July 15, 2010
Last Updated: June 27, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Switzerland: Swissmedic

Keywords provided by EKOS Corporation:
Pulmonary embolism
Pulmonary thromboembolism
anticoagulation
thrombolysis
ultrasound accelerated thrombolysis

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Calcium heparin
Heparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 19, 2013